Alpha-Synuclein Aggregation Pathway

Migration, Crosslink

📖

Alpha-Synuclein Aggregation Pathway

active

wiki page Created: 2026-04-02T07:20:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-alpha-synuclein-aggregat

📖 Wiki Page

mechanism3559 wordssynced 2026-04-02

Alpha-Synuclein Aggregation Pathway

Overview

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation represents one of the central pathological hallmarks of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and related synucleinopathies. The pathological accumulation of misfolded alpha-synuclein protein into Lewy bodies and Lewy neurites characterizes the majority of PD cases and provides a mechanistic link between genetic risk factors and sporadic disease[@spillantini1997]. Understanding the pathways governing alpha-synuclein homeostasis, misfolding, aggregation, and propagation is essential for developing disease-modifying therapies targeting the proteinopathic basis of these neurodegenerative disorders.

The alpha-synuclein protein is encoded by the [SNCA](/genes/snca) gene and is abundant in the brain, particularly in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release. Under physiological conditions, alpha-synuclein exists as a natively unfolded monomer that can adopt alpha-helical conformations upon membrane binding. However, various genetic, environmental, and age-related factors can trigger the protein's misfolding into beta-sheet rich oligomers and fibrils that serve as the building blocks of Lewy pathology[@goedert2017].

...

Alpha-Synuclein Aggregation Pathway

Overview

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation represents one of the central pathological hallmarks of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and related synucleinopathies. The pathological accumulation of misfolded alpha-synuclein protein into Lewy bodies and Lewy neurites characterizes the majority of PD cases and provides a mechanistic link between genetic risk factors and sporadic disease[@spillantini1997]. Understanding the pathways governing alpha-synuclein homeostasis, misfolding, aggregation, and propagation is essential for developing disease-modifying therapies targeting the proteinopathic basis of these neurodegenerative disorders.

The alpha-synuclein protein is encoded by the [SNCA](/genes/snca) gene and is abundant in the brain, particularly in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release. Under physiological conditions, alpha-synuclein exists as a natively unfolded monomer that can adopt alpha-helical conformations upon membrane binding. However, various genetic, environmental, and age-related factors can trigger the protein's misfolding into beta-sheet rich oligomers and fibrils that serve as the building blocks of Lewy pathology[@goedert2017].

The progression of alpha-synuclein pathology follows a predictable pattern in PD, beginning in the lower brainstem and olfactory bulb, advancing to the midbrain (including the substantia nigra), and eventually affecting cortical regions[@braak2003]. This staging system has been validated in multiple cohorts and provides a framework for understanding disease progression.

Molecular Biology of Alpha-Synuclein

Protein Structure and Function

Alpha-synuclein is a 140-amino acid protein encoded by the [SNCA](/genes/snca) gene located on chromosome 4q21. The protein comprises three distinct domains[@fink1996]:

N-terminal region (1-60): Contains seven imperfect repeats of the sequence KTKEGV that mediate lipid binding and form alpha-helical structures upon association with membranes. This region also contains the sites of familial PD mutations (A30P, A53T, E46K, G51D, H50Q).

Central hydrophobic region (61-95): Known as the non-[amyloid-beta](/proteins/amyloid-beta) component (NAC) domain, this region is highly prone to aggregation and is essential for fibril formation. The NAC domain contains residues critical for beta-sheet formation.

C-terminal region (96-140): Acidic and proline-rich, this domain is intrinsically disordered and may serve as a chaperone-like regulatory domain. The C-terminal tail also contains sites for phosphorylation (Ser129) and other post-translational modifications.

Under normal conditions, alpha-synuclein participates in synaptic vesicle pool management, dopamine transmission regulation, and neuronal plasticity. The protein shuttles between cytosolic and membrane-associated pools, with its membrane binding being regulated by post-translational modifications and cellular signaling events[@jensen2019].

Physiological Functions

Beyond its pathological aggregation, alpha-synuclein has important physiological roles:

Regulation of synaptic vesicle trafficking and clustering
Modulation of dopamine synthesis and release
Presynaptic plasticity and long-term potentiation
Calcium homeostasis
Lipid metabolism

Transgenic mice lacking alpha-synuclein show relatively mild phenotypes, suggesting functional redundancy, while overexpression leads to neurodegeneration, highlighting the importance of proper regulation.

Post-Translational Modifications

Alpha-synuclein undergoes numerous post-translational modifications that influence its aggregation propensity[@mak2020]:

Phosphorylation: Phosphorylation at Ser129 is the predominant modification in Lewy bodies, with approximately 90% of pathological alpha-synuclein being phosphorylated at this site. Kinases including G-protein-coupled receptor kinases (GRKs) and casein kinases contribute to this modification. Ser129 phosphorylation promotes fibril formation and may be a therapeutic target.
Ubiquitination: Polyubiquitination targets alpha-synuclein for proteasomal degradation, though Lewy body alpha-synuclein is often conjugated to ubiquitin chains that may be atypical (e.g., Lys63-linked). Ubiquitination may be a marker of cellular stress rather than a degradation signal.
Truncation: C-terminal truncations enhance aggregation propensity and are found in pathological inclusions. Truncated alpha-synuclein (e.g., 1-120) serves as an efficient seed for aggregation of full-length protein.
Oxidation and nitration: Reactive oxygen and nitrogen species can modify tyrosine residues (Y125, Y133, Y136), promoting aggregation. Oxidized alpha-synuclein shows enhanced oligomerization and neurotoxicity.
SUMOylation: SUMOylation at Lys102 and Lys96 modulates aggregation, with SUMOylated alpha-synuclein showing reduced fibrillization.

Mechanisms of Aggregation

Nucleation and Oligomerization

The aggregation of alpha-synuclein follows a nucleation-dependent polymerization model[@schmitt2022]:

Lag phase: Monomeric alpha-synuclein undergoes conformational changes to form transient oligomeric nuclei. This phase can be accelerated by pre-existing seeds ("seeded" aggregation).

Growth phase: Addition of monomers to existing nuclei leads to rapid fibril elongation. The fibrils grow through a "dock-lock" mechanism involving conformational conversion of monomers.

Plateau phase: Equilibrium between monomers, oligomers, and fibrils is reached.

The toxic oligomeric species formed during aggregation are increasingly recognized as the primary neurotoxic entities, rather than the mature fibrils themselves[@hafner2019]. These oligomers can be:

Membrane-permeabilizing: Forming pores that disrupt cellular ion homeostasis
Synaptic disruptors: Impairing neurotransmitter release and reuptake
Mitochondrially toxic: Targeting and damaging mitochondrial function
Prion-like: Capable of seeding further aggregation in a templated manner[@ullah2018]

Oligomer Types and Toxicity

Alpha-synuclein oligomers exist in multiple forms:

Protofibrils: Early oligomeric intermediates that can be circular or chain-like
Annular oligomers: Pore-like structures that disrupt membranes
Spherical oligomers: Diffuse aggregates with varying toxicity
Fibrillar intermediates: On-pathway species that mature into fibrils

The specific oligomer species that are most toxic remains an active area of investigation, but evidence suggests that transient, intermediate oligomers may be particularly pathogenic.

Cellular Quality Control Systems

Multiple cellular pathways attempt to prevent alpha-synuclein aggregation:

| Pathway | Mechanism | Role in PD |
|---------|-----------|------------|
| Ubiquitin-Proasome System (UPS) | Degrades modified alpha-synuclein | Impaired in PD, contributes to accumulation |
| [Autophagy](/entities/autophagy) Pathway (ALP) | Macroautophagy and CMA clear aggregates | Genetic PD risk factors impair ALP function |
| Molecular Chaperones | Hsp70, Hsp40 prevent misfolding | Therapeutic target for enhancement |
| Mitochondrial Quality Control | Mitophagy removes damaged mitochondria | Impaired in PD models |

Prion-Like Propagation

Cell-to-Cell Transmission

A landmark discovery in neurodegeneration research was the recognition that alpha-synuclein pathology can propagate between [neurons](/entities/neurons) in a prion-like manner[@ullah2018]. This process involves:

Release: Alpha-synuclein is released from neurons via exocytosis, exosome secretion, and possibly direct membrane transfer. Release is enhanced by neuronal activity and cellular stress.

Uptake: Recipient cells internalize extracellular alpha-synuclein via various endocytic pathways, including receptor-mediated endocytosis, direct membrane translocation, and phagocytosis.

Seeding: Exogenous alpha-synuclein serves as a template for seeded aggregation of endogenous protein. The conformation of the seed dictates the structure of the resulting aggregates ("strain" concept).

Spread: The process repeats, propagating pathology throughout connected brain regions.

This prion-like propagation provides a mechanistic explanation for the staging of Lewy pathology in the brains of PD patients, which follows a predictable pattern beginning in the lower brainstem and advancing to the midbrain and eventually cortical regions[@braak2003].

Evidence for Prion-Like Spread

Multiple lines of evidence support prion-like propagation:

Lewy bodies can be detected in grafted neurons years after transplantation into PD brains
Animal models show that injected alpha-synuclein seeds endogenous pathology
In vitro experiments demonstrate templated conversion of monomeric alpha-synuclein
Brain-bank studies show progression patterns consistent with spread

Strains and Polymorphisms

Emerging evidence suggests that alpha-synuclein aggregates can adopt distinct conformational "strains" with different biological properties, potentially explaining the clinical heterogeneity of synucleinopathies. These strains may differ in:

Fibril morphology (as seen by cryo-EM)
Seeding potency
Cellular tropism
Pathogenicity

Strains may also influence the clinical phenotype, with certain conformations associated with PD vs. DLB vs. MSA.

Genetic Factors

SNCA Mutations and Multiplications

Point mutations in [SNCA](/genes/snca) (A53T, A30P, E46K, H50Q, G51D) and genomic multiplications cause familial PD, demonstrating that dysregulated alpha-synuclein expression is sufficient to cause neurodegeneration[@polymeropoulos1997][@zarranz2004]:

A53T: Found in the Italian Contursi kindred and several other families, promotes rapid aggregation in cellular and animal models. Leads to early-onset PD (median age 46 years).
A30P: Identified in a German family, reduces membrane binding while promoting aggregation. Associated with variable onset and progression.
E46K: Found in Spanish families, enhances aggregation and affects sleep behavior. Recapitulates Lewy body pathology in mice.
G51D: Rare mutation found in a Japanese family, has complex effects on aggregation and cellular trafficking.
H50Q: Recently identified mutation with intermediate effects on aggregation.
SNCA duplication/triplication: First identified in the Iowa kindred, causes LOADs (late-onset autosomal dominant) form of PD[@singleton2003]. Gene dosage correlates with age of onset, supporting a toxic gain-of-function mechanism.

Risk Variants

Genome-wide association studies (GWAS) have identified common variants at the [SNCA](/genes/snca) locus as significant risk factors for sporadic PD, highlighting the importance of alpha-synuclein biology even in non-familial disease[@krueger2010]. These variants likely influence [SNCA](/genes/snca) expression through regulatory elements in the promoter and intronic regions.

Interactions with Other Proteins

Alpha-Synuclein and Tau

Alpha-synuclein pathology frequently coexists with tau pathology in PD and PD with dementia[@mak2020][@song2019]:

Synergistic toxic effects: Co-aggregation and cross-seeding
Common upstream mechanisms (e.g., oxidative stress, mitochondrial dysfunction)
Shared therapeutic targets

Alpha-Synuclein and Amyloid-Beta

In the presence of amyloid pathology (as in AD), alpha-synuclein aggregation is accelerated:

Amyloid-beta may act as a seed for alpha-synuclein
Shared mechanisms of cellular vulnerability
Implications for PD-AD overlap

Therapeutic Implications

Disease-Modifying Strategies

Targeting alpha-synuclein aggregation represents a promising therapeutic approach[@b2023]:

Immunotherapies: Active and passive immunization approaches targeting alpha-synuclein are in clinical development. Examples include:

PRX002 (prasinezumab): Anti-alpha-synuclein monoclonal antibody
BIIB054 (cinmeron): Antibody targeting oligomeric alpha-synuclein
ACI-35: Liposome-based vaccine targeting phosphorylated Ser129

Small Molecule Inhibitors: Compounds that prevent aggregation or promote clearance include:

Anle138b: Oligomer modulator in clinical trials
NPT200-1: Aggregation inhibitor
SynuClean-D: Dual inhibitor of alpha-synuclein aggregation

Gene Therapy: Viral vector-mediated delivery of genes encoding anti-aggregation proteins or RNA interference targeting [SNCA](/genes/snca) mRNA.

Enhancing Clearance: Strategies to boost autophagy and proteasomal degradation of alpha-synuclein, including:

mTOR inhibitors (rapamycin)
Autophagy inducers (carbamazepine, trehalose)
Gene therapy for chaperone proteins

Targeting Propagation

Emerging strategies target the prion-like spread of alpha-synuclein:

Inhibitors of exosome release
Blocking cell-to-cell transmission
Anti-seed antibodies

Biomarkers

Alpha-Synuclein as Biomarker

Alpha-synuclein in biofluids serves as a PD biomarker:

CSF alpha-synuclein: Reduced total alpha-synuclein in PD; elevated phosphorylated Ser129
Blood/plasma alpha-synuclein: Technical challenges but promising
Skin biopsy: Detection of phosphorylated alpha-synuclein

Seed Amplification Assays

Real-time quaking-induced conversion (RT-QuIC) and PMCA can detect pathological alpha-synuclein with high sensitivity and specificity:

Detects oligomeric/fibrillar species
Differentiates PD from controls
May detect pre-clinical disease

Summary

The alpha-synuclein aggregation pathway represents a central mechanism in Parkinson's disease pathogenesis. The conversion of natively unfolded alpha-synuclein into toxic oligomers and fibrils disrupts multiple cellular processes, including synaptic function, mitochondrial integrity, and proteostasis. The prion-like propagation of pathology provides a framework for understanding disease progression, while the identification of genetic mutations causing familial PD establishes alpha-synuclein dysregulation as a sufficient cause of neurodegeneration. Therapeutic strategies targeting various stages of the aggregation pathway are under active clinical development, offering hope for disease-modifying treatments in Parkinson's disease.

Oligomer Biology and Toxicity

Structural Characterization of Oligomers

Alpha-synuclein oligomers represent a heterogeneous population of prefibrillar species that form during the aggregation process. These oligomers are increasingly recognized as the primary neurotoxic species in Parkinson's disease, rather than the mature fibrils that comprise Lewy bodies. [@lotharius2005]

The structural properties of toxic oligomers include:

Beta-sheet rich conformation: Despite their prefibrillar nature, many oligomers contain beta-sheet secondary structures that distinguish them from natively unfolded monomers

Membrane binding capacity: Oligomers exhibit enhanced binding to neuronal membranes, particularly at synaptic terminals

Dynamic nature: Oligomeric species are transient and can revert to monomers, disaggregate into fibrils, or continue to grow

Surface exposure of hydrophobic regions: The NAC domain becomes more exposed in oligomeric states, enabling membrane interaction and cellular toxicity

Mechanisms of Oligomer-Mediated Neurotoxicity

The toxic effects of alpha-synuclein oligomers on neurons involve multiple interconnected pathways:

Synaptic dysfunction: Oligomeric alpha-synuclein localizes to presynaptic terminals where it disrupts synaptic vesicle trafficking and recycling. Studies in transgenic mice demonstrate that oligomer accumulation correlates with progressive loss of synaptic proteins and impaired neurotransmitter release. [@masliah2000]

Calcium dysregulation: Oligomers can form calcium-permeable pores in neuronal membranes, leading to dysregulated calcium homeostasis. This calcium influx activates downstream pathways including calpain-mediated proteolysis and mitochondrial permeability transition.

Mitochondrial dysfunction: Alpha-synuclein oligomers directly bind to mitochondrial membranes and impair complex I activity. [@bookout2020] This creates a vicious cycle where mitochondrial dysfunction increases oxidative stress, which in turn promotes further alpha-synuclein aggregation.

Endoplasmic reticulum stress: Oligomer accumulation in the endoplasmic reticulum triggers the unfolded protein response (UPR) and promotes apoptotic signaling through CHOP and caspase activation.

Targeting Oligomers Therapeutically

Given the central role of oligomers in pathogenesis, several therapeutic strategies specifically target these species:

Oligomer-specific antibodies: Antibodies that selectively recognize oligomeric conformations over monomers or fibrils
Small molecule modulators: Compounds like anle138b that shift the aggregation pathway away from toxic oligomers toward inert species
Seeding inhibitors: Molecules that prevent oligomeric seeds from propagating

Fibril Structure and Lewy Body Formation

Atomic Structure of Alpha-Synuclein Fibrils

Cryo-electron microscopy studies have revealed the atomic structure of alpha-synuclein fibrils, demonstrating that they adopt a cross-beta sheet architecture. The fibril core comprises residues 31-100, forming a double phi-loop structure that stabilizes the fibril. [@giasson2002]

Key structural features include:

Steric zipper: The interface between beta-sheets creates a "steric zipper" motif characteristic of amyloid fibrils
Residue-specific folding: The NAC region (residues 61-95) forms the fibril core
Polymorphic strains: Different preparation conditions and cellular environments produce structurally distinct fibril morphologies

Lewy Body Composition and Maturation

Lewy bodies are complex intracellular inclusions comprising fibrillar alpha-synuclein along with numerous other proteins, lipids, and cellular components. Their formation represents a failed attempt at cellular clearance:

Early stage: Hyperphosphorylated alpha-synuclein accumulates at the presynaptic terminal

Intermediate stage: Ubiquitinated oligomers and fibrils aggregate into visible inclusions

Late stage: Mature Lewy bodies contain a dense core surrounded by a halo of radiating filaments

The presence of numerous proteins in Lewy bodies reflects the broader disruption of cellular proteostasis in Parkinson's disease. [@pokaly2002]

Cellular and Molecular Interactors

Protein Partners in Aggregation

Alpha-synuclein aggregation is modulated by interactions with numerous cellular proteins:

| Protein | Interaction | Effect on Aggregation |
|---------|-------------|----------------------|
| Tau | Co-aggregation in AD/PD | Synergistic toxicity |
| Amyloid-beta | Cross-seeding in AD/PD | Enhanced pathology |
| Hsp70/Hsp40 | Chaperone binding | Inhibition of aggregation |
| 14-3-3 proteins | Phospho-Ser129 binding | May stabilize oligomers |
| Rab proteins | Synaptic vesicle association | Facilitates propagation |

Lipid Interactions and Membrane Effects

The interaction of alpha-synuclein with lipid membranes is a critical aspect of its biology:

Membrane binding: The N-terminal region binds to negatively charged phospholipids
Membrane-induced folding: Lipid binding induces alpha-helical conformation
Membrane disruption: Aggregated species can permeabilize membranes
Raft association: Localization to lipid rafts may facilitate prion-like spread

Environmental and Lifestyle Factors

Risk Factors Promoting Aggregation

Various environmental and lifestyle factors influence alpha-synuclein aggregation:

Neurotoxin exposure: MPTP, rotenone, and other mitochondrial toxins promote alpha-synuclein pathology in experimental models, linking environmental exposures to disease pathogenesis.

Aging: The decline in cellular clearance mechanisms with age creates a permissive environment for protein aggregation. Decreased autophagy, proteasome activity, and chaperone function all contribute. [@voutsinas2010]

Head trauma: Traumatic brain injury is associated with increased PD risk and may accelerate alpha-synuclein pathology through blood-brain barrier disruption and neuroinflammation.

Protective Factors

Several factors may reduce aggregation risk:

Physical exercise: Promotes autophagy and enhances cellular clearance
Caffeine: May reduce aggregation through adenosine receptor antagonism
Anti-inflammatory drugs: Reduce neuroinflammation that promotes aggregation

Neuroinflammation and Glial Interactions

Microglial Activation

Alpha-synuclein pathology activates microglia through multiple mechanisms:

Direct recognition: Microglial TLR2 and TLR4 recognize aggregated alpha-synuclein

Complement activation: Opsonization with complement proteins promotes phagocytosis

Cytokine release: Activated microglia release TNF-alpha, IL-1beta, and IL-6

The resulting neuroinflammation creates a feed-forward loop where inflammatory cytokines promote further alpha-synuclein misfolding and release. [@schmitt2022]

Astrocyte Involvement

Astrocytes also participate in the response to alpha-synuclein pathology:

Uptake and clearance: Astrocytes can internalize extracellular alpha-synuclein
Inflammatory signaling: Activated astrocytes release pro-inflammatory mediators
Metabolic support: Astrocytic dysfunction may reduce neuronal metabolic support

Interaction with Other Proteinopathies

Tau Co-Pathology

The co-occurrence of alpha-synuclein and tau pathology is common, particularly in certain clinical variants. The interaction between these two proteins includes:

Cross-seeding: Tau fibrils can catalyze alpha-synuclein aggregation and vice versa
Synergistic toxicity: Combined pathology produces greater neuronal loss
Distinct anatomical patterns: Lewy bodies and neurofibrillary tangles follow different anatomical distributions

Amyloid-beta Interaction

In brains with both AD and PD pathology, amyloid-beta may influence alpha-synuclein aggregation:

Modulation of aggregation kinetics: Amyloid-beta can accelerate or inhibit alpha-synuclein fibril formation depending on conditions
Shared pathways: Both proteins involve similar cellular clearance mechanisms (UPS, autophagy) [@cool2013]

Clinical Implications

Diagnostic Biomarkers

Alpha-synuclein aggregation provides potential biomarkers:

Cerebrospinal fluid: Decreased alpha-synuclein and increased oligomers in PD
Skin biopsies: Phospho-Ser129 alpha-synuclein in cutaneous nerves
Blood-based markers: Alpha-synuclein in extracellular vesicles

Disease Progression Markers

The extent of alpha-synuclein pathology correlates with clinical severity:

Braak staging: Predicts clinical progression based on anatomical spread
Oligomer levels: Correlate with cognitive impairment in PD
Lewy body density: Associated with faster disease progression

Autophagy Enhancement Strategies

The autophagy-lysosome pathway (ALP) represents a critical clearance mechanism for alpha-synuclein. Both macroautophagy and chaperone-mediated autophagy (CMA) contribute to intracellular alpha-synuclein turnover. [@chen2019]

Macroautophagy induction: mTOR inhibitors like rapamycin promote autophagy and reduce alpha-synuclein accumulation in cellular and animal models.

CMA activation: Enhancement of CMA can specifically target alpha-synuclein for lysosomal degradation, as the protein contains a CMA recognition motif.

Lysosomal function: Maintaining lysosomal acidity and enzyme activity is essential for effective clearance of alpha-synuclein aggregates. [@xilouri2009]

Mitochondrial Quality Control

Given the intimate relationship between alpha-synuclein and mitochondrial dysfunction, targeting mitochondrial quality control represents a promising approach:

Complex I protection: Preserving mitochondrial complex I activity reduces oxidative stress and alpha-synuclein aggregation
Mitophagy induction: Enhancing PINK1/Parkin-mediated mitophagy removes dysfunctional mitochondria
Antioxidant therapy: Mitochondrial-targeted antioxidants like MitoQ address oxidative damage

These strategies address both the downstream consequences and upstream drivers of alpha-synuclein pathology. [@schapira2013]

Several novel approaches are under investigation:

Seed-specific inhibitors: Molecules that specifically block templated aggregation

Autophagy enhancers: Compounds that boost cellular clearance of alpha-synuclein

RNA-based therapies: ASOs and siRNA targeting SNCA mRNA

Cellular replacement: Strategies to replace lost neurons using stem cells

Biomarker Development

Improving diagnosis and tracking disease progression:

Strain-specific detection: Distinguishing different alpha-synuclein conformations
Real-time monitoring: PET ligands for alpha-synuclein pathology
Multimodal markers: Combining alpha-synuclein with other biomarkers

α-Synuclein Aggregation Pathway

Mermaid diagram (expand to render)

References

Unknown (n.d.)

[Spillantini et al., Alpha-synuclein in Lewy bodies (1997)](https://doi.org/10.1038/42166)

[Goedert et al., The synucleinopathies: Twenty years on (2017)](https://doi.org/10.1093/brain/awx056)

[Braak et al., Staging of brain pathology related to sporadic Parkinson's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12610656/)

[Jensen et al., Propagation of alpha-synuclein pathology (2019)](https://doi.org/10.1016/j.neuron.2019.04.031)

[Mak et al., Alpha-synuclein and tau pathology (2020)](https://doi.org/10.1007/s00401-020-02168-0)

[Schmitt et al., Alpha-synuclein in immune cells (2022)](https://doi.org/10.1038/s41582-022-00639-4)

[Brundin et al., Targeting alpha-synuclein for PD therapy (2023)](https://doi.org/10.1038/s41582-023-00761-9)

[Bookout et al., Alpha-synuclein and mitochondrial dysfunction (2020)](https://pubmed.ncbi.nlm.nih.gov/32976578/)

[Davie et al., A review of Parkinson's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18293108/)

[Lotharius et al., Pathogenesis and therapy of alpha-synucleinopathies (2005)](https://pubmed.ncbi.nlm.nih.gov/16033316/)

[Warner et al., Genomic cloning and chromosomal assignment of the human alpha-synuclein gene (1997)](https://pubmed.ncbi.nlm.nih.gov/9328456/)

[Li et al., Alpha-synuclein and the pathogenesis of Parkinson's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15878454/)

[Masliah et al., Dopaminergic loss and inclusion body formation in alpha-synuclein transgenic mice (2000)](https://pubmed.ncbi.nlm.nih.gov/10781069/)

[Giasson et al., A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein (2002)](https://pubmed.ncbi.nlm.nih.gov/11835695/)

[Serpell et al., Axonal dysfunction in the pathogenesis of Parkinson's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10652573/)

[Chen et al., Alpha-synuclein and autophagy in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31820756/)

[Xilouri et al., Alpha-synuclein and autophagy: A tail of two pathways (2009)](https://pubmed.ncbi.nlm.nih.gov/19158486/)

[Voutsinas et al., Protein homeostasis and aging (2010)](https://pubmed.ncbi.nlm.nih.gov/20471809/)

[Cool et al., Alpha-synuclein and the UPS in synucleinopathies (2013)](https://pubmed.ncbi.nlm.nih.gov/23684758/)

[Schapira et al., Targeting mitochondria for neuroprotection in Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23277352/)

[Lang et al., Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24896908/)

[Kalia et al., Parkinson's disease: Etiology, neuropathology, and pathogenesis (2015)](https://pubmed.ncbi.nlm.nih.gov/26746186/)

[Pokaly et al., Alpha-synuclein in Lewy body disease (2002)](https://pubmed.ncbi.nlm.nih.gov/11835463/)

Cross-Linking

[Alpha-synuclein](/proteins/alpha-synuclein)
[SNCA](/genes/snca)
[Parkinson's Disease](/diseases/parkinsons-disease)
[TREM2](/proteins/trem2-protein)
[LRRK2](/genes/lrrk2)
[Autophagy Pathway](/mechanisms/autophagy-lysosome-pathway)
[Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-pd)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1

📖 View canonical wiki page →

Related Entities

mechanisms-alpha-synuclein-aggregation

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-alpha-synuclein-aggregation
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-88e3b1be5994
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-alpha-synuclein-aggregation'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

55

Outgoing

74

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alpha-Synuclein Aggregation Pathway

Alpha-Synuclein Aggregation Pathway

Overview

Alpha-Synuclein Aggregation Pathway

Overview

Molecular Biology of Alpha-Synuclein

Protein Structure and Function

Physiological Functions

Post-Translational Modifications

Mechanisms of Aggregation

Nucleation and Oligomerization

Oligomer Types and Toxicity

Cellular Quality Control Systems

Prion-Like Propagation

Cell-to-Cell Transmission

Evidence for Prion-Like Spread

Strains and Polymorphisms

Genetic Factors

SNCA Mutations and Multiplications

Risk Variants

Interactions with Other Proteins

Alpha-Synuclein and Tau

Alpha-Synuclein and Amyloid-Beta

Therapeutic Implications

Disease-Modifying Strategies

Targeting Propagation

Biomarkers

Alpha-Synuclein as Biomarker

Seed Amplification Assays

Summary

Oligomer Biology and Toxicity

Structural Characterization of Oligomers

Mechanisms of Oligomer-Mediated Neurotoxicity

Targeting Oligomers Therapeutically

Fibril Structure and Lewy Body Formation

Atomic Structure of Alpha-Synuclein Fibrils

Lewy Body Composition and Maturation

Cellular and Molecular Interactors

Protein Partners in Aggregation

Lipid Interactions and Membrane Effects

Environmental and Lifestyle Factors

Risk Factors Promoting Aggregation

Protective Factors

Neuroinflammation and Glial Interactions

Microglial Activation

Astrocyte Involvement

Interaction with Other Proteinopathies

Tau Co-Pathology

Amyloid-beta Interaction

Clinical Implications

Diagnostic Biomarkers

Disease Progression Markers

Autophagy Enhancement Strategies

Mitochondrial Quality Control

Biomarker Development

α-Synuclein Aggregation Pathway

See Also

References

Cross-Linking

Related Hypotheses

💬 Discussion